These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33465692)

  • 1. Himalayan bioactive molecules as potential entry inhibitors for the human immunodeficiency virus.
    Kumar Bhardwaj V; Purohit R; Kumar S
    Food Chem; 2021 Jun; 347():128932. PubMed ID: 33465692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.
    Lin G; Bertolotti-Ciarlet A; Haggarty B; Romano J; Nolan KM; Leslie GJ; Jordan AP; Huang CC; Kwong PD; Doms RW; Hoxie JA
    J Virol; 2007 Sep; 81(18):9956-66. PubMed ID: 17609282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Viral entry as therapeutic target. Current situation of entry inhibitors].
    Arenzana-Seisdedos F
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
    Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
    J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs.
    Seibert C; Sakmar TP
    Curr Pharm Des; 2004; 10(17):2041-62. PubMed ID: 15279544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
    Panos G; Watson DC
    Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor Interactions.
    Giroud C; Marin M; Hammonds J; Spearman P; Melikyan GB
    J Virol; 2015 Sep; 89(18):9368-82. PubMed ID: 26136569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
    Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
    J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential regulation of CXCR4 and CCR5 expression by interleukin (IL)-4 and IL-13 is associated with inhibition of chemotaxis and human immunodeficiency Virus (HIV) type 1 replication but not HIV entry into human monocytes.
    Creery D; Weiss W; Graziani-Bowering G; Kumar R; Aziz Z; Angel JB; Kumar A
    Viral Immunol; 2006; 19(3):409-23. PubMed ID: 16987060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
    Hunt JS; Romanelli F
    Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
    Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
    Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.
    Derdeyn CA; Decker JM; Sfakianos JN; Zhang Z; O'Brien WA; Ratner L; Shaw GM; Hunter E
    J Virol; 2001 Sep; 75(18):8605-14. PubMed ID: 11507206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV co-receptors as targets for antiviral therapy.
    Schols D
    Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
    Princen K; Schols D
    Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Putative cholesterol-binding sites in human immunodeficiency virus (HIV) coreceptors CXCR4 and CCR5.
    Zhukovsky MA; Lee PH; Ott A; Helms V
    Proteins; 2013 Apr; 81(4):555-67. PubMed ID: 23161741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemokines as natural HIV antagonists.
    Verani A; Lusso P
    Curr Mol Med; 2002 Dec; 2(8):691-702. PubMed ID: 12462390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a cell-based enzyme-linked immunosorbent assay for high-throughput screening of HIV type 1 entry inhibitors targeting the coreceptor CXCR4.
    Zhao Q; Lu H; Schols D; De Clercq E; Jiang S
    AIDS Res Hum Retroviruses; 2003 Nov; 19(11):947-55. PubMed ID: 14678601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
    Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
    J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sphingomyelinase restricts the lateral diffusion of CD4 and inhibits human immunodeficiency virus fusion.
    Finnegan CM; Rawat SS; Cho EH; Guiffre DL; Lockett S; Merrill AH; Blumenthal R
    J Virol; 2007 May; 81(10):5294-304. PubMed ID: 17344303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
    AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.